Marvel Biosciences Announces Second Quarter 2022 Financial Results
Calgary, Alberta--(Newsfile Corp. - March 30, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") today announced its financial results for the second quarter ended January 31, 2022. For further information on these results, please see the Marvel Biosciences Corp. Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis as filed on SEDAR."During the quarter ended...
2022-03-30 4:37 PM EDT
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
Calgary, Alberta--(Newsfile Corp. - February 16, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report the proxy tabulation ("Tabulation") from Odyssey Trust Company in connection with its Annual and Special Meeting of Shareholders held virtually on February 15, 2022 (the "Meeting"), as well as results from the Meeting.The Tabulation is the final sum of the voting results of the...
2022-02-16 11:48 AM EST
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
Calgary, Alberta--(Newsfile Corp. - February 15, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report the proxy tabulation ("Tabulation") from Odyssey Trust Company in connection with its Annual and Special Meeting of Shareholders held virtually on February 15, 2022 (the "Meeting"), as well as results from the Meeting.The Tabulation is the final sum of the voting results of the...
2022-02-15 4:30 PM EST
Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase
Calgary, Alberta--(Newsfile Corp. - February 8, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") is pleased to provide a corporate update on the operations of the business. OverviewThe Company is pursuing a well-known and proven to be effective strategy of redeveloping existing and approved drugs to target new indications and diseases. This is a de-risked approach to drug development, as often,...
2022-02-08 9:00 AM EST
Marvel Biosciences Corp. Announces Change of Chief Financial Officer
Calgary, Alberta--(Newsfile Corp. - February 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") is pleased to announce the appointment of Harry Nijjar, CPA, CMA, as Chief Financial Officer of the Company, effective February 1, 2022, replacing Preston Maddin who left the Company effective January 31, 2022.Mr. Nijjar joined Malaspina Consultants Inc. in 2011 and is currently a Managing Director. Malaspina Consultants Inc. has been engaged by the Corporation to provide...
2022-02-01 9:00 AM EST
Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204
Calgary, Alberta--(Newsfile Corp. - December 16, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a multi-kilogram engineering run of its lead MB-204 asset by Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The engineering run material will be used for its ongoing toxicology studies of MB-204 being conducted by Pharmaron Inc. ("Pharmaron"). Pharmaron's...
2021-12-16 9:00 AM EST
Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound
Calgary, Alberta--(Newsfile Corp. - December 8, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its pre-clinical investigational new drug ("IND") enabling toxicology studies for its lead compound MB-204 with Pharmaron, Inc. ("Pharmaron"), with its principal office in Louisville, Kentucky.Pharmaron, one of the world's largest contract research...
2021-12-08 9:00 AM EST
Marvel Biosciences to Host Investor Webinar
Calgary, Alberta--(Newsfile Corp. - November 29, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it will host an investor webinar via Zoom on Wednesday, December 1, 2021 at 1:00pm EST. The presentation will feature President and Chief Scientific Officer Mark Williams, who will walk through the investor presentation and provide an update on the business. A question and...
2021-11-29 9:00 AM EST
Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash
Calgary, Alberta--(Newsfile Corp. - November 23, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis ("NASH") using fibrosis and the non-alcoholic fatty liver disease activity score (NAS score) endpoints that are analogous to the known approvable NASH endpoints...
2021-11-23 9:00 AM EST
Marvel Biosciences Appoints Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - November 9, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce the creation of its scientific advisory board to help guide the development of its lead asset, MB-204, a fluorinated derivative of the US-FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the...
2021-11-09 8:00 AM EST
Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds
Calgary, Alberta--(Newsfile Corp. - October 27, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives...
2021-10-27 9:00 AM EDT
Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones
Calgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient ("API") of its lead drug MB-204, the Company has now entered an important milestone of engineering and subsequent current good manufacturing practices ("cGMP") run of its multi-kilogram...
2021-10-15 9:00 AM EDT
Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer's Drug Discovery
Calgary, Alberta--(Newsfile Corp. - September 17, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has been accepted to present at the start-up company forum at the 22nd International Conference of Alzheimer's Drug Discovery, a virtual conference on October 4 and 5th, 2021 hosted by the Alzheimer's Drug Discovery Foundation.The 2020 conference attracted close to 900...
2021-09-17 9:00 AM EDT
Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases
Calgary, Alberta--(Newsfile Corp. - August 5, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to provide an update on its lead compound asset MB-204 ("MB-204") being developed for neurological conditions such as depression and anxiety, Alzheimer's and ADHD. Marvel's compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson's disease drug Istradefylline...
2021-08-05 9:00 AM EDT
Marvel Biosciences Corp. Retains Virtus Advisory Group to Provide Corporate Communications Services
Calgary, Alberta--(Newsfile Corp. - August 3, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") is pleased to announce that it has retained Virtus Advisory Group Inc. ("Virtus") to develop and implement a strategic corporate communications program to increase the Company's exposure among industry stakeholders and investors across Canada. In connection with the engagement, Virtus has been awarded a consulting contract that includes a monthly fee of $7,000 and a grant of...
2021-08-03 4:30 PM EDT
Marvel Biosciences Corp. to Commence cGMP Manufacturing of Its Lead Asset MB-204
Calgary, Alberta--(Newsfile Corp. - July 21, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that the Company's wholly owned subsidiary, Marvel Biotechnology Inc., has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology Inc. has entered into a current good manufacturing process (cGMP) manufacturing agreement (the "Agreement") with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun") for the...
2021-07-21 8:30 AM EDT
Alphanco Venture Corp. Changes Name to Marvel Biosciences Corp. and Completes Acquisition of Marvel Biotechnology Inc.
Calgary, Alberta--(Newsfile Corp. - July 8, 2021) - Alphanco Venture Corp. (TSXV: AVC.P) (the "Company" or "AVC"), a capital pool company listed on the TSX Venture Exchange (the "TSXV"), is pleased to announce that it has closed its proposed "Qualifying Transaction," as defined under TSXV policies, being the acquisition of all of the outstanding shares (the "Transaction") of Marvel Biotechnology Inc., ("Marvel Biotech") effective June 14, 2021. In connection with closing of the Qualifying...
2021-07-08 1:24 PM EDT